Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

被引:16
作者
Guo, Yongjun [1 ]
Ma, Jie [1 ]
Lyu, Xiaodong [1 ]
Liu, Hai [2 ]
Wei, Bing [1 ]
Zhao, Jiuzhou [1 ]
Fu, Shuang [3 ]
Ding, Lu [4 ]
Zhang, Jihong [3 ]
机构
[1] Zhengzhou Univ, Affiliated Tumor Hosp, Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China
[2] Henan Prov Publ Secur Bur, Inst Forens Sci & Technol, Zhengzhou 450003, Henan, Peoples R China
[3] China Med Univ, Shengjing Hosp, Hematol Malignancy Treatment Ctr, Hematol Lab, Shenyang 100022, Liaoning, Peoples R China
[4] Shanghai Yuanqi Biopharmaceut Co Ltd, Shanghai 201403, Peoples R China
关键词
Non-small-cell lung cancers (NSCLCs); Anaplastic lymphoma kinase (ALK); Echinoderm microtubule-associated protein-like 4 (EML4); Tyrosine kinase inhibitors (TKIs); Never-smokers; Adenocarcinoma; FUSION GENE; ALK; MUTATIONS; EGFR; IDENTIFICATION; TRANSCRIPTS; KIF5B-ALK;
D O I
10.1186/1471-2407-14-834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations. It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK. Thus, characterization of EML4-ALK fusion genes and clinical features of resulting carcinomas would be a great benefit to disease diagnosis and designing customized treatment plans. Studies have suggested that EML4-ALK translocation occurs more frequently in never-smokers with NSCLC, especially in female patients. However, it is not clear whether this is the case in male patients, too. In this study, we have determined the frequency of EML4-ALK translocation in male never-smokers with NSCLC in a cohort of Chinese patients. The clinical features associated with EML4-ALK translocation were also investigated. Methods: A cohort of 95 Chinese male never-smokers with NSCLC was enrolled in this study. EML4-ALK fusion genes were detected using one-step real time RT-PCR and DNA sequencing. We further determined the expression levels of ALK mRNA by RT-PCR and ALK protein by immunohistochemistry in these specimens. The clinical features of EML4-ALK-positive carcinomas were also determined. Results: We have identified EML4-ALK fusion genes in 8 out of 95 carcinoma cases, accounting for 8.42% in Chinese male never-smokers with NSCLC. It is significantly higher than that in all Chinese male patients (3.44%) regardless smoking habit. It is also significantly higher than that in all Chinese smokers (8/356 or 2.25%) or in smokers worldwide (2.9%) by comparing to published data. Interestingly, EML4-ALK fusion genes are more frequently found in younger patients and associated with less-differentiated carcinomas. Conclusions: The frequency of EML4-ALK translocation is strongly associated with smoking habits in Chinese male patients with higher frequency in male never-smokers. EML4-ALK translocation is associated with early-onset and less-differentiated carcinomas.
引用
收藏
页数:10
相关论文
共 32 条
[1]  
[Anonymous], CA CANC J CLIN, DOI DOI 10.3322/CAAC.20107
[2]  
[Anonymous], 2013, PLOS ONE, DOI DOI 10.1371/JOURNAL.PONE.0077864
[3]   Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas [J].
Boland, Jennifer M. ;
Erdogan, Sibel ;
Vasmatzis, George ;
Yang, Ping ;
Tillmans, Lori S. ;
Johnson, Michele R. Erickson ;
Wang, Xiaoke ;
Peterson, Lisa M. ;
Halling, Kevin C. ;
Oliveira, Andre M. ;
Aubry, Marie Christine ;
Yi, Eunhee S. .
HUMAN PATHOLOGY, 2009, 40 (08) :1152-1158
[4]   Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer [J].
Choi, Young Lim ;
Takeuchi, Kengo ;
Soda, Manabu ;
Inamura, Kentaro ;
Togashi, Yuki ;
Hatano, Satoko ;
Enomoto, Munehiro ;
Hamada, Toru ;
Haruta, Hidenori ;
Watanabe, Hideki ;
Kurashina, Kentaro ;
Hatanaka, Hisashi ;
Ueno, Toshihide ;
Takada, Shuji ;
Yamashita, Yoshihiro ;
Sugiyama, Yukihiko ;
Ishikawa, Yuichi ;
Mano, Hiroyuki .
CANCER RESEARCH, 2008, 68 (13) :4971-4976
[5]   EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers [J].
Inamura, Kentaro ;
Takeuchi, Kengo ;
Togashi, Yuki ;
Nomura, Kimie ;
Ninomiya, Hironori ;
Okui, Michiyo ;
Satoh, Yukitoshi ;
Okumura, Sakae ;
Nakagawa, Ken ;
Soda, Manabu ;
Choi, Young Lim ;
Niki, Toshiro ;
Mano, Hiroyuki ;
Ishikawa, Yuichi .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :13-17
[6]   EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset [J].
Inamura, Kentaro ;
Takeuchi, Kengo ;
Togashi, Yuki ;
Hatano, Satoko ;
Ninomiya, Hironori ;
Motoi, Noriko ;
Mun, Ming-yon ;
Sakao, Yukinori ;
Okumura, Sakae ;
Nakagawa, Ken ;
Soda, Manabu ;
Choi, Young Lim ;
Mano, Hiroyuki ;
Ishikawa, Yuichi .
MODERN PATHOLOGY, 2009, 22 (04) :508-515
[7]   Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma [J].
Jokoji, Ryu ;
Yamasaki, Takashi ;
Minami, Seigo ;
Komuta, Kiyoshi ;
Sakamaki, Yasushi ;
Takeuchi, Kengo ;
Tsujimoto, Masahiko .
JOURNAL OF CLINICAL PATHOLOGY, 2010, 63 (12) :1066-1070
[8]   KIF5B-RET fusions in lung adenocarcinoma [J].
Kohno, Takashi ;
Ichikawa, Hitoshi ;
Totoki, Yasushi ;
Yasuda, Kazuki ;
Hiramoto, Masaki ;
Nammo, Takao ;
Sakamoto, Hiromi ;
Tsuta, Koji ;
Furuta, Koh ;
Shimada, Yoko ;
Iwakawa, Reika ;
Ogiwara, Hideaki ;
Oike, Takahiro ;
Enari, Masato ;
Schetter, Aaron J. ;
Okayama, Hirokazu ;
Haugen, Aage ;
Skaug, Vidar ;
Chiku, Suenori ;
Yamanaka, Itaru ;
Arai, Yasuhito ;
Watanabe, Shun-ichi ;
Sekine, Ikuo ;
Ogawa, Seishi ;
Harris, Curtis C. ;
Tsuda, Hitoshi ;
Yoshida, Teruhiko ;
Yokota, Jun ;
Shibata, Tatsuhiro .
NATURE MEDICINE, 2012, 18 (03) :375-377
[9]   EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer [J].
Koivunen, Jussi P. ;
Mermel, Craig ;
Zejnullahu, Kreshnik ;
Murphy, Carly ;
Lifshits, Eugene ;
Holmes, Alison J. ;
Choi, Hwan Geun ;
Kim, Jhingook ;
Chiang, Derek ;
Thomas, Roman ;
Lee, Jinseon ;
Richards, William G. ;
Sugarbaker, David J. ;
Ducko, Christopher ;
Lindeman, Neal ;
Marcoux, J. Paul ;
Engelman, Jeffrey A. ;
Gray, Nathanael S. ;
Lee, Charles ;
Meyerson, Matthew ;
Janne, Pasi A. .
CLINICAL CANCER RESEARCH, 2008, 14 (13) :4275-4283
[10]   Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer [J].
Kwak, Eunice L. ;
Bang, Yung-Jue ;
Camidge, D. Ross ;
Shaw, Alice T. ;
Solomon, Benjamin ;
Maki, Robert G. ;
Ou, Sai-Hong I. ;
Dezube, Bruce J. ;
Jaenne, Pasi A. ;
Costa, Daniel B. ;
Varella-Garcia, Marileila ;
Kim, Woo-Ho ;
Lynch, Thomas J. ;
Fidias, Panos ;
Stubbs, Hannah ;
Engelman, Jeffrey A. ;
Sequist, Lecia V. ;
Tan, WeiWei ;
Gandhi, Leena ;
Mino-Kenudson, Mari ;
Wei, Greg C. ;
Shreeve, S. Martin ;
Ratain, Mark J. ;
Settleman, Jeffrey ;
Christensen, James G. ;
Haber, Daniel A. ;
Wilner, Keith ;
Salgia, Ravi ;
Shapiro, Geoffrey I. ;
Clark, Jeffrey W. ;
Iafrate, A. John .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) :1693-1703